10 reasons why to use bisoprolol Review article
Article Sidebar
Published:
Jun 20, 2022
Keywords:
hypertension, heart failure, β-blockers, bisoprolol
Main Article Content
Abstract
Β-blockers are a very often used group of drugs in patients with heart failure, hypertension, or cardiac arrhythmias. Among them, the most used is bisoprolol, which results from its antihypertensive efficacy, lowering the heart rate, but most importantly in reducing cardiovascular risk, including the risk of death from any cause among patients with heart failure with a reduced ejection fraction. In the article I have included the most important reasons, supported by the results of clinical trials, why it is worth using bisoprolol among our patients.
Article Details
How to Cite
Balsam , P. (2022). 10 reasons why to use bisoprolol. Medycyna Faktow (J EBM), 15(2(55), 148-152. https://doi.org/10.24292/01.MF.0222.5
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353(9146): 9-13.
2. Lechat P, Escolano S, Golmard JL et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation. 1997; 96(7): 2197-205.
3. Dubach P, Myers J, Bonetti P et al. Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging. Am Heart J. 2002; 143(4): 676-83.
4. Maisch B, Borst U, Gerhards W et al. Effect of bisoprolol on cardiac performance in coronary heart disease. Eur J Clin Pharmacol. 1989; 36(3): 217-22.
5. Woroń J, Kostka-Trąbka E. The erectile dysfunction as a effect of adverse drug reactions. Seksuologia Polska. 2005; 3(1): 5.
6. Mustafaev II, Nurmamedova GS. [Effect of monotherapy with nebivolol, bisoprolol, carvedilol on the state of vegetative nervous system and sexual function in men with arterial hypertension]. Kardiologiia. 2013; 53(2): 48-54.
7. Filipiak KJ. Bisoprolol–amlodipine fix-dosed combinations – examples of treatment scenarios. Choroby Serca i Naczyń. 2015; 12(4): 5.
8. Contini M, Apostolo A, Cattadori G et al. Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial. Int J Cardiol. 2013; 168(3): 2134-40.
9. Czuriga I, Riecansky I, Bodnar J et al. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther. 2003; 17(3): 257-63.
2. Lechat P, Escolano S, Golmard JL et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation. 1997; 96(7): 2197-205.
3. Dubach P, Myers J, Bonetti P et al. Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging. Am Heart J. 2002; 143(4): 676-83.
4. Maisch B, Borst U, Gerhards W et al. Effect of bisoprolol on cardiac performance in coronary heart disease. Eur J Clin Pharmacol. 1989; 36(3): 217-22.
5. Woroń J, Kostka-Trąbka E. The erectile dysfunction as a effect of adverse drug reactions. Seksuologia Polska. 2005; 3(1): 5.
6. Mustafaev II, Nurmamedova GS. [Effect of monotherapy with nebivolol, bisoprolol, carvedilol on the state of vegetative nervous system and sexual function in men with arterial hypertension]. Kardiologiia. 2013; 53(2): 48-54.
7. Filipiak KJ. Bisoprolol–amlodipine fix-dosed combinations – examples of treatment scenarios. Choroby Serca i Naczyń. 2015; 12(4): 5.
8. Contini M, Apostolo A, Cattadori G et al. Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial. Int J Cardiol. 2013; 168(3): 2134-40.
9. Czuriga I, Riecansky I, Bodnar J et al. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther. 2003; 17(3): 257-63.